Beijing Yimiao Shenzhou Pharmaceutical Technology
Developer of AVV cell therapy for the treatment of cancer. Beijing Yimiao Shenzhou Pharmaceutical Technology is a developer of AVV cell therapy for the treatment of cancer. It offers treatment for malignant tumors by the application of CART-T technology and gene cell drugs. It also develops a gene engineering vector technology platform for the delivery of lentiviral vectors for the preparation of CAR-T cell…
Funding snapshot
About
Developer of AVV cell therapy for the treatment of cancer. Beijing Yimiao Shenzhou Pharmaceutical Technology is a developer of AVV cell therapy for the treatment of cancer. It offers treatment for malignant tumors by the application of CART-T technology and gene cell drugs. It also develops a gene engineering vector technology platform for the delivery of lentiviral vectors for the preparation of CAR-T cell products. Its products include IM19, IM21, and IM23 which are in the clinical stage. The company operates in the Life Sciences > Genomics, Life Sciences > Immunotherapy sector. Founded in 2015 and headquartered in Haidian, China and has raised $42.8 million in Series D funding. Key investors include China Life Insurance, GF Securities, AAMA Chamber of Commerce, SDIC Venture Capital Management, Longmenfund, Shuimushenan, Shougang Fund, Sherpa Venture Capital.
Business model
Oncology > Drugs > Diversified,
Genomics > Applied Genomics > Clinical Genomics > Therapeutics
Team background
College Wise > Tsinghua University
Institutional investors
Backed by funds in our directory
Latest coverage
No articles yet.
Similar startups
Immuneel
Developer of T-cell therapies for the treatment of cancer. It is developing cell therapies by using genetic engineering that modifies healthy immune cells to target cancerous cells.
ImmunoACT
Developer of cell and gene therapies for cancer treatment. It offers a lead product NexCAR19 Talicabtagene autoleucel for B‑cell malignancies such as B‑lymphoma and B‑acute lymphoblastic leukaemia.
HaystackAnalytics
EmbeDL is a provider of an edge AI optimization and deployment platform that streamlines the path from deep learning model development to hardware-ready deployment on embedded systems.
4baseCare
Sitehop is a provider of hardware-enforced network encryption solutions that delivers ultra-low latency, quantum-ready encryption for data-in-motion in critical networks through its SAFE Series product line.
Raising like Beijing Yimiao Shenzhou Pharmaceutical Technology?
Analyze your pitch deck before your next raise.
Analyze My Deck →